4 completed, 1 recruiting. 3 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow CKD Bio Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease L. lactis CKDB001, Placebo - Early Alzheimers Disease | Not applicable | Recruiting | CKD Bio Corporation | 60 | 2026-02-23 | 2026-03-30 |
| Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial CKDB-501A, Botox® - Glabellar Lines | Phase 3 | Completed | CKD Bio Corporation | 300 | 2023-04-13 | 2023-12-12 |
| Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines CKDB-501B, Botox®50U - Glabellar Lines | Phase 1 | Completed | CKD Bio Corporation | 30 | 2022-06-22 | 2022-11-17 |
| Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity CKDB-501A, Botox® - Post-stroke Upper Limb Spasticity | Phase 1 | Completed | CKD Bio Corporation | 24 | 2022-06-02 | 2023-03-28 |
| Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines CKDB-501A, Botox® - Glabellar Lines | Phase 1 | Completed | CKD Bio Corporation | 30 | 2022-02-15 | 2022-11-17 |
South Korea (5)
Beomjoon Kim (1) · Woo Jung Kim (1)